Asuragen Revenue and Competitors

Austin, TX USA

Location

$80M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Asuragen's estimated annual revenue is currently $23.9M per year.(i)
  • Asuragen's estimated revenue per employee is $175,515
  • Asuragen's total funding is $80M.

Employee Data

  • Asuragen has 136 Employees.(i)
  • Asuragen grew their employee count by 2% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M6200%N/AN/A
#2
$15.8M10234%N/AN/A
#3
$15.2M983%$1.8MN/A
#4
$2.8M18-25%N/AN/A
#5
$3.4M220%N/AN/A
#6
$2.6M1755%N/AN/A
#7
$7.6M4923%N/AN/A
#8
$0.9M6-33%N/AN/A
#9
$1.6M10-9%N/AN/A
#10
$1.1M7-42%N/AN/A
Add Company

Asuragen, Inc. is a newly formed company that resulted from the sale, in March, 2006, of the Research Products Division of Ambion, Inc. to Applied Biosystems Group (NYSE: ABI). Asuragen is comprised of two of Ambion's former divisions, Diagnostics and Services, along with the formation of a new Discovery group dedicated to developing new technologies that will become cutting edge clinical products. This will significantly expand Asuragen's current product portfolio, which consists of Signature(R) Genetic Testing and Oncology Testing products, as well as industry leading controls and standards engineered using its patented Armored RNA(R) technology. Asuragen has recently formed a partnership with Digene Corporation (NASDAQ: DIGE) to market and distribute its Signature cystic fibrosis screening products. The vision for Asuragen is to become a fully integrated diagnostic reagent company focused on molecular oncology and early detection of cancer, with emphasis in microRNAs. Comprised of over 100 employees from a well-established company, Asuragen is empowered with not only scientific expertise, but also assay development, business infrastructure and an established cGMP manufacturing facility that allow it to span the spectrum of discovery, production and commercialization.

keywords:Biotechnology

$80M

Total Funding

136

Number of Employees

$23.9M

Revenue (est)

2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Asuragen News

2022-04-06 - Diagnostics PCR Market Size, Scope And Forecast | Leading ...

Abbott Laboratories, Agilent Technologies Inc., Abbott, Asuragen, Biocartis Group Nv, Biofire Diagnostics, Llc. (Acquired By Biomerieux),...

2008-04-03 - Life-science briefing: Thursday, April 3, 2008

TODAY’S HEADLINES: Mirna Thera spins out of Asuragen with $3M (release) Stroke-therapy startup CoAxia raises $12M (release) Stealthy device maker Synvascular gets $6.5M (peHUB) AndroScience seeks $3.5M for anti-testosterone drugs (VentureWire) Austria’s ProtAffin takes in €1.1M grant (release) S ...

2007-12-10 - Life sciences briefing: Monday, Dec. 10, 2007

TODAY’S HEADLINES: Fundamental Applied Biology pulls in $21M for proteins without cells (release) Diagnostics maker Asuragen receives $19M (release) Stroke-device maker Neurovasx raises $8.5M (release) Cancer-vaccine maker ImmunoVaccine Tech buys Immunotope, seeks $15M (release) Vascular im ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$19M136N/AN/A
#2
$18.5M13613%$14M
#3
$17.7M136-3%$33.5M
#4
$54.4M136-6%N/A
#5
$7.5M1365%N/A

Asuragen Executives


NameTitle
BERNARD AndrussChief Operations Officer
Gary LathamChief Scientific Officer
Lynne HohlfeldSVP, Corporate Development and Chief Financial Officer
Debra ThompsonVP HR
Tom CopaSVP Commercial operations
Dana ScofieldVice President of Finance and Controller
Hilary Graham MAVice President, Marketing and Product Management
Ruth SanfordVP Marketing, Product Management, Customer Experience and Customer Service
Jenny ManuelVice President, General Counsel
Lynne HohlfeldSVP, Corporate Development and Chief Financial Officer